{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:16:23Z","timestamp":1792062983605,"version":"4.4.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Importance<\/jats:title>\n Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from the American Heart Association Get With The Guidelines\u2013Stroke quality improvement registry. Patients with ICH who presented within 24 hours of symptom onset across 465 US hospitals from 2015 to 2021 were included. Data were analyzed from January to September 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Anticoagulation-associated ICH.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n DTT times and outcomes were analyzed using logistic regression modeling, adjusted for demographic, history, baseline, and hospital characteristics, with hospital-specific random intercepts to account for clustering by site. The primary outcome of interest was the composite inpatient mortality and discharge to hospice. Additional prespecified secondary outcomes, including functional outcome (discharge modified Rankin Scale score, ambulatory status, and discharge venue), were also examined.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 9492 patients with anticoagulation-associated ICH and documented reversal intervention status, 4232 (44.6%) were female, and the median (IQR) age was 77 (68-84) years. A total of 7469 (78.7%) received reversal therapy, including 4616 of 5429 (85.0%) taking warfarin and 2856 of 4069 (70.2%) taking a non\u2013vitamin K antagonist oral anticoagulant. For the 5224 patients taking a reversal intervention with documented workflow times, the median (IQR) onset-to-treatment time was 232 (142-482) minutes and the median (IQR) DTT time was 82 (58-117) minutes, with a DTT time of 60 minutes or less in 1449 (27.7%). A DTT time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82; 95% CI, 0.69-0.99) but no difference in functional outcome (ie, a modified Rankin Scale score of 0 to 3; adjusted odds ratio, 0.91; 95% CI, 0.67-1.24). Factors associated with a DTT time of 60 minutes or less included White race, higher systolic blood pressure, and lower stroke severity.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In US hospitals participating in Get With The Guidelines\u2013Stroke, earlier anticoagulation reversal was associated with improved survival for patients with ICH. These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.0221","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T12:30:28Z","timestamp":1707481828000},"page":"363","source":"Crossref","is-referenced-by-count":93,"title":["Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage"],"prefix":"10.1001","volume":"81","author":[{"given":"Kevin N.","family":"Sheth","sequence":"first","affiliation":[{"name":"Yale Center for Brain and Mind Health, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Solomon","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Messe","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas at Southwestern, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Claude","family":"Hemphill","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Frontera","sequence":"additional","affiliation":[{"name":"Department of Neuology, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Chang","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya M.","family":"Danelich","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Huang","sequence":"additional","affiliation":[{"name":"AstraZeneca, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwamm","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics and Data Sciences, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mac Grory","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ronald Reagan UCLA Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Saver","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ronald Reagan UCLA Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"noi240009r1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMra2201449","article-title":"Spontaneous intracerebral hemorrhage.","volume":"387","author":"Sheth","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240009r2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"noi240009r3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal.","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"noi240009r4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors.","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240009r5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"issue":"10395","key":"noi240009r6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(23)00806-1","article-title":"The Third Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.","volume":"402","author":"Ma","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"noi240009r7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"issue":"16","key":"noi240009r8","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/jama.2014.3203","article-title":"Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.","volume":"311","author":"Fonarow","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"noi240009r9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/svn-2017-000092","article-title":"The American Heart Association\u2019s Get With The Guidelines (GWTG)\u2013Stroke development and impact on stroke care.","volume":"2","author":"Ormseth","year":"2017","journal-title":"Stroke Vasc Neurol"},{"issue":"3","key":"noi240009r10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ahj.2011.12.012","article-title":"Data quality in the American Heart Association Get With The Guidelines\u2013Stroke (GWTG-Stroke): results from a national data validation audit.","volume":"163","author":"Xian","year":"2012","journal-title":"Am Heart J"},{"issue":"3","key":"noi240009r11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/CIRCOUTCOMES.109.921858","article-title":"Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With The Guidelines\u2013Stroke.","volume":"3","author":"Fonarow","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"noi240009r12","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1161\/STR.0000000000000171","article-title":"Clinical performance measures for adults hospitalized with intracerebral hemorrhage: performance measures for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"49","author":"Hemphill","year":"2018","journal-title":"Stroke"},{"issue":"9","key":"noi240009r13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/STROKEAHA.112.660415","article-title":"Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.","volume":"43","author":"Menon","year":"2012","journal-title":"Stroke"},{"issue":"15","key":"noi240009r14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1161\/CIRCULATIONAHA.109.932822","article-title":"Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With The Guidelines\u2013Stroke Program.","volume":"122","author":"Smith","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"noi240009r15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2015.3106","article-title":"Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator.","volume":"73","author":"Xian","year":"2016","journal-title":"JAMA Neurol"},{"issue":"14","key":"noi240009r16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1212\/01.wnl.0000326895.58992.27","article-title":"Warfarin use leads to larger intracerebral hematomas.","volume":"71","author":"Flaherty","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"noi240009r17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/ana.v86.4","article-title":"An intracerebral hemorrhage care bundle is associated with lower case fatality.","volume":"86","author":"Parry-Jones","year":"2019","journal-title":"Ann Neurol"},{"issue":"6","key":"noi240009r19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/emermed-2012-201471","article-title":"The face arm speech test: does it encourage rapid recognition of important stroke warning symptoms?","volume":"30","author":"Robinson","year":"2013","journal-title":"Emerg Med J"},{"issue":"11","key":"noi240009r20","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1161\/STROKEAHA.107.490078","article-title":"A randomized, controlled trial to teach middle school children to recognize stroke and call 911: the kids identifying and defeating stroke project.","volume":"38","author":"Morgenstern","year":"2007","journal-title":"Stroke"},{"issue":"6","key":"noi240009r21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1212\/WNL.56.6.766","article-title":"Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies.","volume":"56","author":"Becker","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"noi240009r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104552","article-title":"Early stroke recognition and time-based emergency care performance metrics for intracerebral hemorrhage.","volume":"29","author":"Colton","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"noi240009r18","unstructured":"American Heart Association. Phase III Target: Stroke: higher goals for greater good. Accessed November 20, 2023. https:\/\/www.heart.org\/-\/media\/files\/professional\/quality-improvement\/target-stroke\/target-stroke-phase-iii\/ts-phase-iii-5-6-19\/final5619-target-stroke-phase-3-brochure.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2815044\/jamaneurology_sheth_2024_oi_240009_1711137412.96018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:01:42Z","timestamp":1712574102000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2815044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.0221","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}